In immune checkpoint inhibitor–related liver injury with persistent alkaline phosphatase elevation at 3–6 months, how do you use biopsy evidence of duct-centered injury/cholangitis to choose between adding ursodeoxycholic acid with a prolonged taper versus earlier transition to non- steroid immunosuppression?